Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: results of two‐centre prospective study

Authors:

Abstract
Summary: Paroxysmal nocturnal haemoglobinuria (PNH) clones are frequently detected in patients with aplastic anaemia (AA). To evaluate the prognostic role ofPNHclone presence we conducted a prospective study in 125AApatients treated with combined immunosuppressive therapy (IST). Seventy‐four patients (59%) had aPNHclone (PNH+ patients) at diagnosis, with a median clone size of 0·60% in granulocytes and 0·15% in red blood cells. The response rate at 6 months was higher inPNH+ patients than that inPNH‐ patients, both after first‐ and second‐lineIST: 68% vs. 45%,P = 0·0164 and 53% vs. 13%,P = 0·0502 respectively. Moreover, 42% ofPNH+ patients achieved complete remission compared with only 16% ofPNH‐ patients (P = 0·0029). In multivariate logistic regression analysis,PNHclone presence (odds ratio 2·56,P = 0·0180) and baseline absolute reticulocyte count (ARC) ≥30 × 109/l (odds ratio 5·19,P = 0·0011) were independent predictors of response to treatment. Stratification according toPNHpositivity andARC≥30 × 109/l showed significant distinctions for cumulative incidence of response, overall and failure‐free survival. The results of this prospective study confirmed the favourable prognostic value ofPNHclone presence in the setting ofISTforAA.

This publication has 35 references indexed in Scilit: